Brachytherapy as a curative option for ocular surface squamous neoplasia.
Brachytherapy
Intraocular OSSN
OSSN
Ruthenium
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
27
03
2022
accepted:
12
11
2022
medline:
24
5
2023
pubmed:
28
11
2022
entrez:
27
11
2022
Statut:
ppublish
Résumé
Ocular surface squamous neoplasia (OSSN) has a high recurrence rate if only treated with surgical excision, especially in cases with positive excision margins. To reduce recurrence, we used brachytherapy after surgical excision for limbal and bulbar lesions in addition to chemotherapy/immunotherapy, cryotherapy, or external beam radiotherapy as adjunctive or primary therapies. Nine eyes with isolated OSSN lesions were included in the study. Adjunctive brachytherapy with Ruthenium The average age of patients at the time of presentation was 66 ± 12 years. Follow-up time was 52.8 ± 44.6 months. The maximal tumour base varied between 3 and 28 mm. SCC was confirmed by histology in all cases. No recurrences were recorded during the follow-up, and organ salvage and eye function preservation were achieved. Radiotherapy-induced complications included secondary glaucoma (n = 1) and scleral melting (n = 1). Other complications, such as radiogenic retinopathy, were not observed. Brachytherapy with Ruthenium
Identifiants
pubmed: 36436169
doi: 10.1007/s10792-022-02585-y
pii: 10.1007/s10792-022-02585-y
doi:
Substances chimiques
Ruthenium
7UI0TKC3U5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1861-1865Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Gichuhi S et al (2013) Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health 18(12):1424–1443
doi: 10.1111/tmi.12203
pubmed: 24237784
pmcid: 4440345
Tunc M et al (1999) Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases. Br J Ophthalmol 83(1):98–103
doi: 10.1136/bjo.83.1.98
pubmed: 10209445
pmcid: 1722787
Shields JA, Shields CL, De Potter P (1997) Surgical management of conjunctival tumors. The 1994 Lynn B McMahan lecture. Arch Ophthalmol 115(6):808–15
doi: 10.1001/archopht.1997.01100150810025
pubmed: 9194740
Stone DU, Butt AL, Chodosh J (2005) Ocular surface squamous neoplasia: a standard of care survey. Cornea 24(3):297–300
doi: 10.1097/01.ico.0000138834.42489.ba
pubmed: 15778602
Adler E, Turner JR, Stone DU (2013) Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea 32(12):1558–1561
doi: 10.1097/ICO.0b013e3182a6ea6c
pubmed: 24145630
Ben Simon GJ et al (2005) Orbital exenteration: one size does not fit all. Am J Ophthalmol 139(1):11–17
doi: 10.1016/j.ajo.2004.07.041
pubmed: 15652823
Lopez Garcia JS et al (2000) Squamous cell carcinoma of the conjunctiva with orbital invasion. Arch Soc Esp Oftalmol 75(9):637–641
pubmed: 11151237
Shields JA et al (1999) The 1998 pan american lecture intraocular invasion of conjunctival squamous cell carcinoma in five patients. Ophthalmic Plast Reconstr Surg 15(3):153–60
doi: 10.1097/00002341-199905000-00003
pubmed: 10355832
Al Bayyat G et al (2019) Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond) 6:24
doi: 10.1186/s40662-019-0150-5
pubmed: 31417938
Ghaffari R et al (2021) Recombinant interferon alpha-2b as primary treatment for ocular surface squamous neoplasia. J Curr Ophthalmol 33(3):260–265
doi: 10.4103/2452-2325.329089
pubmed: 34765812
pmcid: 8579786
Galor A et al (2010) Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol 94(5):551–554
doi: 10.1136/bjo.2008.153197
pubmed: 19493859
Birkholz ES et al (2011) Treatment of ocular surface squamous cell intraepithelial neoplasia with and without Mitomycin C. Cornea 30(1):37–41
doi: 10.1097/ICO.0b013e3181dee560
pubmed: 20861726
Joag MG et al (2016) Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology 123(7):1442–1448
doi: 10.1016/j.ophtha.2016.02.034
pubmed: 27030104
Li AS et al (2015) Recurrence of ocular surface squamous neoplasia treated with excisional biopsy and cryotherapy. Am J Ophthalmol 160(2):213–219
doi: 10.1016/j.ajo.2015.04.027
pubmed: 25914042
Arepalli S et al (2014) Plaque radiotherapy in the management of scleral-invasive conjunctival squamous cell carcinoma: an analysis of 15 eyes. JAMA Ophthalmol 132(6):691–696
doi: 10.1001/jamaophthalmol.2014.86
pubmed: 24557333
Kenawy N et al (2015) Conjunctival squamous cell neoplasia: the Liverpool ocular oncology centre experience. Graefes Arch Clin Exp Ophthalmol 253(1):143–150
doi: 10.1007/s00417-014-2860-7
pubmed: 25398663
Rao R et al (2021) Histopathology-guided management of ocular surface squamous neoplasia with corneal stromal or scleral invasion using Ruthenium
Tabin G et al (1997) Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology 104(3):485–492
doi: 10.1016/S0161-6420(97)30287-5
pubmed: 9082277
Iovieno A et al (2009) Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression. Cornea 28(7):821–824
doi: 10.1097/ICO.0b013e318190937d
pubmed: 19574900
Bahrami B, Greenwell T, Muecke JS (2014) Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Clin Exp Ophthalmol 42(4):317–322
doi: 10.1111/ceo.12184
pubmed: 23927413